ATE488520T1 - Pyrazolopyrimidine, ein verfahren zu ihrer herstellung und ihre verwendung als medizin - Google Patents

Pyrazolopyrimidine, ein verfahren zu ihrer herstellung und ihre verwendung als medizin

Info

Publication number
ATE488520T1
ATE488520T1 AT07788197T AT07788197T ATE488520T1 AT E488520 T1 ATE488520 T1 AT E488520T1 AT 07788197 T AT07788197 T AT 07788197T AT 07788197 T AT07788197 T AT 07788197T AT E488520 T1 ATE488520 T1 AT E488520T1
Authority
AT
Austria
Prior art keywords
pyrazolopyrimidines
medicine
production
Prior art date
Application number
AT07788197T
Other languages
English (en)
Inventor
Wojciech Danysz
Andrzej Dekundy
Mirko Hechenberger
Markus Henrich
Claudia Jatzke
Jens Nagel
Christopher Graham Raphael Parsons
Tanja Weil
Juris Fotins
Aleksandra Gutcaits
Ivars Kalvinsh
Ronalds Zemribo
Valerjans Kauss
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Application granted granted Critical
Publication of ATE488520T1 publication Critical patent/ATE488520T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
AT07788197T 2006-08-04 2007-08-03 Pyrazolopyrimidine, ein verfahren zu ihrer herstellung und ihre verwendung als medizin ATE488520T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83582006P 2006-08-04 2006-08-04
US87754406P 2006-12-28 2006-12-28
PCT/EP2007/058061 WO2008015270A1 (en) 2006-08-04 2007-08-03 Pyrazolopyrimidines, a process for their preparation and their use as medicine

Publications (1)

Publication Number Publication Date
ATE488520T1 true ATE488520T1 (de) 2010-12-15

Family

ID=38710494

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07788196T ATE494289T1 (de) 2006-08-04 2007-08-03 Substituierte pyrazolopyrimidine, ein verfahren zu ihrer herstellung und ihre verwendung als medizin
AT07788197T ATE488520T1 (de) 2006-08-04 2007-08-03 Pyrazolopyrimidine, ein verfahren zu ihrer herstellung und ihre verwendung als medizin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT07788196T ATE494289T1 (de) 2006-08-04 2007-08-03 Substituierte pyrazolopyrimidine, ein verfahren zu ihrer herstellung und ihre verwendung als medizin

Country Status (21)

Country Link
US (4) US20080032998A1 (de)
EP (3) EP2054416B8 (de)
JP (2) JP2010500288A (de)
KR (1) KR20090047450A (de)
AR (3) AR062210A1 (de)
AT (2) ATE494289T1 (de)
AU (2) AU2007280428B2 (de)
BR (2) BRPI0714766A2 (de)
CA (2) CA2659871A1 (de)
CY (1) CY1112003T1 (de)
DE (2) DE602007011773D1 (de)
DK (1) DK2054416T3 (de)
HR (1) HRP20110128T1 (de)
IL (2) IL196008A0 (de)
MX (2) MX2009001036A (de)
PL (1) PL2054416T3 (de)
PT (1) PT2054416E (de)
RU (2) RU2450004C2 (de)
TW (3) TW200823215A (de)
WO (3) WO2008015270A1 (de)
ZA (1) ZA200810605B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008056176A1 (en) * 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines as phosphodiesterase inhibitors
JP5856990B2 (ja) * 2007-03-31 2016-02-10 インターベット インターナショナル ベー． フェー． ジルパテロールおよびこの塩の製造方法
EP2090576A1 (de) * 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-Pyrazolo[1,5-a]pyridin-Verbindungen, Verfahren zu ihrer Herstellung und Verwendung als Modulatoren des Metabotropen Glutamatrezeptoren (mGluR)
WO2010000763A2 (en) * 2008-06-30 2010-01-07 Novartis Ag Combination products
EP2504340A1 (de) 2009-11-25 2012-10-03 Merz Pharma GmbH & Co. KGaA Kristalline formen von substituierten pyrazolopyrimidinen
US8703946B2 (en) 2010-12-08 2014-04-22 Vanderbilt University Substituted pyrazolo[1,5-A]pyrazine compounds as allosteric modulators of mGluR5 receptors
WO2012125732A1 (en) * 2011-03-15 2012-09-20 Vanderbilt University Substituted imadazapyrinidin-5(6h)-ones as allosteric modulators of mglur5 receptors
US8865725B2 (en) 2011-03-15 2014-10-21 Vanderbilt University Substituted imidazopyrimidin-5(6H)-ones as allosteric modulators of MGLUR5 receptors
WO2012139876A1 (en) 2011-04-14 2012-10-18 Merz Pharma Gmbh & Co. Kgaa Enteric formulations of metabotropic glutamate receptor modulators
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013087808A1 (en) 2011-12-15 2013-06-20 Merz Pharma Gmbh & Co. Kgaa Pharmaceutical composition comprising a pyrazolopyrimidme and cyclodextrin
WO2013087815A1 (en) 2011-12-15 2013-06-20 Merz Pharma Gmbh & Co. Kgaa Liquid pharmaceutical composition containing a pyrazolopyrimidine derivative and pharmaceutical uses thereof
US9006235B2 (en) 2012-03-06 2015-04-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9029360B2 (en) * 2012-03-29 2015-05-12 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines as metabotropic glutamate 5 receptor antagonists
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
JP2015529206A (ja) 2012-08-25 2015-10-05 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｇａｐｄｈカスケードインヒビター化合物ならびに使用の方法および精神病を含むストレス誘導障害の処置
MD20150071A2 (ro) 2013-02-19 2016-02-29 Pfizer Inc. Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
JP2016512511A (ja) 2013-03-13 2016-04-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヒト免疫不全ウイルス複製の阻害剤
JP2016516692A (ja) 2013-03-13 2016-06-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヒト免疫不全ウイルス複製の阻害剤
EP2970297A1 (de) 2013-03-14 2016-01-20 Bristol-Myers Squibb Company Hemmer der neubildung menschlicher immundefektviren
EP3036219A4 (de) * 2013-06-04 2017-08-23 Temple University Of The Commonwealth System Of Higher Education Neuartige beta-lactame als modulatoren einer glutamataufnahme und verfahren zur verwendung davon
US10398142B2 (en) 2013-11-05 2019-09-03 Temple University Of The Commonwealth System Of Higher Education Polycationic amphiphiles as antimicrobial agents
JP2016537418A (ja) 2013-11-05 2016-12-01 テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイアー エデュケーション 抗菌剤としてのポリカチオン両親媒性物質
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
US9273067B2 (en) 2014-02-19 2016-03-01 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
EA031201B1 (ru) 2014-08-06 2018-11-30 Пфайзер Инк. Соединения имидазопиридазина
BR112018015386A2 (pt) 2016-01-27 2019-03-19 Universität Zürich uso de moduladores de receptor gabaa para tratamento de prurido

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7305644A (de) 1972-04-20 1973-10-23
GB1383409A (en) 1972-09-09 1974-02-12 Pfizer Ltd Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them
US3988339A (en) 1974-02-08 1976-10-26 Smithkline Corporation Pharmaceutical compositions and methods of inhibiting phenylethanolamine N-methyltransferase
US3974283A (en) * 1974-03-18 1976-08-10 Sandoz, Inc. N-substituted-4-T-butyl-1-pyridinethiocarboxamides and their use for treatment of inflammation or pain
NZ190915A (en) * 1978-07-31 1984-07-31 Hoffmann La Roche Oxadiazolotriazine derivatives and pharmaceutical compositions
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US4340597A (en) * 1981-04-13 1982-07-20 Schering Corporation 1-Substituted-4-aryl-1,2,5,6-tetrahydro and hexahydropyridines
DE3308554A1 (de) * 1983-03-10 1984-09-13 Hoechst Ag, 6230 Frankfurt 1-/1,3-dioxolan-2-ylmethyl)-azole, ihre salze, verfahren zu ihrer herstellung und ihre verwendung
WO1989005643A1 (en) * 1987-12-18 1989-06-29 Pfizer Inc. Heterocyclic-substituted quinoline-carboxylic acids
DE10299048I2 (de) 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
US6177443B1 (en) * 1997-03-07 2001-01-23 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use
UA61962C2 (uk) 1997-06-30 2003-12-15 Мерц Фарма Гмбх Унд Ко. Кгаа Сполука 1-аміноалкілциклогексану, фармацевтична композиція на її основі та спосіб лікування
US6071966A (en) 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
DE19732589A1 (de) * 1997-07-29 1999-02-04 Huels Chemische Werke Ag Verfahren zur Herstellung von 1,2,3,6-tetrahydro-2,2,6,6-tetramethylpyridin
FR2769313B1 (fr) * 1997-10-06 2000-04-21 Sanofi Sa Derives d'esters hydroxyacetiques, leur procede de preparation et leur utilisation comme intermediaires de synthese
AU771358B2 (en) 1997-11-21 2004-03-18 Astrazeneca Ab Metabotropic glutamate receptor antagonists for treating central nervous system diseases
WO1999033804A1 (en) * 1997-12-25 1999-07-08 Meiji Seika Kaisha, Ltd. Tetrahydrobenzindole derivatives
CA2342251A1 (en) 1998-08-28 2000-03-09 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
US20020049223A1 (en) 1999-11-05 2002-04-25 Elmore Steven W. Quinoline and naphthyridine carboxylic acid antibacterials
ES2246922T3 (es) * 1999-12-28 2006-03-01 Eisai Co., Ltd. Compuestos heterociclicos que tienen grupos de sulfonamida.
GB0110338D0 (en) 2001-04-27 2001-06-20 Sb Pharmco Inc Novel processes
GB0118752D0 (en) * 2001-08-01 2001-09-26 Pfizer Ltd Process for the production of quinazolines
EP1506196B1 (de) * 2001-11-01 2012-01-18 Icagen, Inc. Pyrazolopyrimidine als natriumkanalblocker
CA2483306A1 (en) 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
MY133587A (en) * 2002-05-29 2007-11-30 Glaxo Group Ltd Aromatic sulfones and their medical use
WO2003101993A1 (en) 2002-06-04 2003-12-11 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
AU2003264018A1 (en) * 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
WO2004089415A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
EP1615697A2 (de) * 2003-04-11 2006-01-18 Novo Nordisk A/S Neue pyrazolo[1,5-a] pyrimidin-derivate und deren pharmazeutische verwendungen
US8197819B2 (en) 2004-06-08 2012-06-12 Novartis Vaccines And Diagnostics, Inc. Env polypeptide complexes and methods of use
DE502005003491D1 (de) 2004-08-02 2008-05-08 Sanol Arznei Schwarz Gmbh Carboxamide des indolizins und seiner aza- und diazaderivate
US20090048285A1 (en) 2005-01-19 2009-02-19 Benjamin Pelcman Pyrrolopyridines Useful in the Treatment of Inflammation

Also Published As

Publication number Publication date
US20080039476A1 (en) 2008-02-14
CA2659876A1 (en) 2008-02-07
JP2009545569A (ja) 2009-12-24
DE602007010640D1 (de) 2010-12-30
AR062210A1 (es) 2008-10-22
EP2054416B1 (de) 2011-01-05
EP2054421B1 (de) 2010-11-17
US20110212956A1 (en) 2011-09-01
KR20090047450A (ko) 2009-05-12
US20080039458A1 (en) 2008-02-14
TW200823215A (en) 2008-06-01
BRPI0714622A2 (pt) 2013-04-30
US20080032998A1 (en) 2008-02-07
AU2007280429A1 (en) 2008-02-07
DK2054416T3 (da) 2011-04-04
MX2009001036A (es) 2009-04-23
US7947689B2 (en) 2011-05-24
IL196007A0 (en) 2009-09-01
JP2010500288A (ja) 2010-01-07
ZA200810605B (en) 2009-12-30
WO2008015270A1 (en) 2008-02-07
EP2295439A1 (de) 2011-03-16
RU2450004C2 (ru) 2012-05-10
AR063680A1 (es) 2009-02-11
RU2009107686A (ru) 2010-09-10
PT2054416E (pt) 2011-04-06
RU2009107688A (ru) 2010-09-10
AU2007280428A1 (en) 2008-02-07
DE602007011773D1 (de) 2011-02-17
WO2008015271A1 (en) 2008-02-07
AR062209A1 (es) 2008-10-22
IL196008A0 (en) 2009-09-01
HRP20110128T1 (hr) 2011-03-31
CY1112003T1 (el) 2015-11-04
MX2009000919A (es) 2009-04-16
TW200817394A (en) 2008-04-16
PL2054416T3 (pl) 2011-05-31
WO2008015269A1 (en) 2008-02-07
ATE494289T1 (de) 2011-01-15
EP2054416A1 (de) 2009-05-06
AU2007280428B2 (en) 2012-04-12
US7985753B2 (en) 2011-07-26
EP2054416B8 (de) 2014-07-16
BRPI0714766A2 (pt) 2013-07-16
CA2659871A1 (en) 2008-02-07
TW200815432A (en) 2008-04-01
TWI399376B (zh) 2013-06-21
EP2054421A1 (de) 2009-05-06

Similar Documents

Publication Publication Date Title
ATE494289T1 (de) Substituierte pyrazolopyrimidine, ein verfahren zu ihrer herstellung und ihre verwendung als medizin
ATE471325T1 (de) Imidazoä1,2-büpyridazine, verfahren zu ihrer herstellung und ihre verwendung als gaba-rezeptor-liganden
ATE463484T1 (de) Tricyclische n-heteroaryl-carboxamid-derivate mit einer benzimidazol-einheit, verfahren zu ihrer herstellung und ihre therapeutische verwendung
ATE470666T1 (de) Arylsubstituierte heterozyklen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP2084249A4 (de) Brennstoffzusammensetzungen mit farnesan und farnesanderivaten sowie verfahren zu ihrer herstellung und verwendung
ATE381564T1 (de) Arylsubstituierte polycyclische amine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP1840113A4 (de) Schichtenförmiges, in wasser abziehbares doppelhydroxid und verfahren zu dessen herstellung und dessen verwendung
DE502005007840D1 (de) 7-phenylamino-4-chinolon-3-carbonsäure-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP2069389A4 (de) Glucanasen, nukleinsäuren zu ihrer kodierung sowie verfahren zu ihrer herstellung und verwendung
DE602008002158D1 (de) Verbundwerkstoffe und verfahren zu ihrer herstellung
DE102006057312A8 (de) Verbundrohr und Verfahren zu seiner Herstellung
ATE441638T1 (de) 4,5-diphenyl-pyrimidinyl substituierte carbonsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE602006020386D1 (de) Duraimplantat und Verfahren zu seiner Herstellung
DE502004011957D1 (de) Neue cyanopyrrolidide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE102007031935B8 (de) Bauteil mit funktionellen Elementen sowie Verfahren zu dessen Herstellung
ATE505469T1 (de) 7-alkynyl-1,8-naphthyridon-derivate, verfahren zu ihrer herstellung und ihre verwendung für therapeutika
ATE348609T1 (de) Tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
EP1906468A4 (de) Batteriedose und verfahren zu ihrer herstellung
ATE535510T1 (de) Benzylamine, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmende mittel
ATE517092T1 (de) Tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
DE602005014250D1 (de) Mehrlagenschaltung mit variablem Induktor sowie Verfahren zu ihrer Herstellung
EP1874463A4 (de) Auf säurefunktionalisiertem festem träger verankerter nanokatalysator und verfahren zu seiner herstellung und verwendung
DE602005001132D1 (de) Geformter Schichtstoff und Verfahren zu dessen Herstellung
ATE509923T1 (de) Derivate von 7-alkynyl-1,8-naphthyridonen, verfahren zu ihrer herstellung und ihre verwendung in therapeutika
ATE520696T1 (de) Tricyclische pyridinderivate, solche verbindungen enthaltende medikamente, ihre verwendung und verfahren zu ihrer herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2054421

Country of ref document: EP